<DOC>
	<DOC>NCT00219180</DOC>
	<brief_summary>To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension</brief_summary>
	<brief_title>Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg &amp; 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Inclusion Criteria Patients with essential hypertension Patients who are eligible and able to participate in the study Exclusion Criteria Severe hypertension History or evidence of a secondary form of hypertension History of Hypertensive encephalopathy or cerebrovascular accident Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hypertension, Aliskiren</keyword>
</DOC>